Tocilizumab, hospital prevalence as a mortality risk factor, antiplatelet therapy, WHO statement on booster doses

Peer reviewed journals featured:

- Systematic reviews on:
  - Tocilizumab for the treatment of hospitalised COVID-19 patients [here](#)
  - Rapid diagnosis of COVID-19 in the first year of the pandemic [here](#)
- A randomised clinical trial of convalescent plasma in critically ill COVID-19 patients [here](#)
- Modelling studies on:
  - Asymptomatic individuals and their impact on epidemic size [here](#)
  - Government interventions against resurgence of COVID-19 in Europe [here](#)
- Observational studies on:
  - COVID-19 hospital prevalence as a risk factor for mortality [here](#)
  - Antiplatelet therapy in COVID-19 [here](#)
  - Post-acute COVID-19 syndrome following mild SARS-CoV-2 infection [here](#)
  - Tocilizumab reduces COVID-19 mortality based on dose and timing-dependent [here](#)
  - Effect of COVID-19 lockdowns on planned cancer surgery for 15 tumour types [here](#)
- Commentary on a UK Research Ethics Committee review of SARS-CoV-2 human infection challenge studies [here](#)

Pre-peer review articles featured:

- Preterm outcomes following COVID-19 lockdowns in Melbourne, Australia [here](#) and [here](#)
- A modelling study on non-pharmaceutical interventions and vaccinating school children in Delta variant outbreaks in Australia [here](#)
- Frequency of surveillance testing necessary to reduce Delta variant transmission [here](#)
- Initial SARS-CoV-2 viral load is associated with disease severity [here](#)
- COVID-19 neutralising antibody testing in fully vaccinated people during Delta variant spread [here](#)
- Effectiveness of Spikevax (Moderna) against Delta, Mu, and other emerging variants [here](#)
- Adverse events of special interest for COVID-19 vaccines [here](#)
Guidance and reports

- The World Health Organization published:
  - Guidance on infection prevention and control during healthcare when COVID-19 is suspected or confirmed [here](#).
  - Its latest COVID-19 epidemiological report [here](#).
  - An interim statement on booster doses for COVID-19 vaccination [here](#).
- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#).

News and blogs

- Confronting future pandemics [here](#).
- Unpacking vaccine “hesitancy” [here](#).
- COVID-19 vaccines cut the risk of transmitting Delta, but not for long [here](#).

Click [here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on COVID-19 transmission, SARS-CoV-2 vaccines, and variants of concern, post-acute sequelae of COVID-19 (PASC), surgery and COVID-19, rapid testing and risk mitigation strategies.